Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398778 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1POLBL3MBTL3L3MBTL1 | |
| SCHEMBL6397400 | 0.86 | GRIN2B (0.46) | KDM4EALDH1A1SLC18A3 | |
| SCHEMBL6397408 | 0.86 | GRIN2B (0.46) | KDM4EALDH1A1SLC18A3 | |
| SCHEMBL13042918 | 0.78 | RAB9A (0.47) | ALDH1A1POLBKMT2ASLC18A3ACE | |
| SCHEMBL6397681 | 0.77 | ACHE (0.54) | KDM4EL3MBTL3L3MBTL1KMT2ASLC18A3 | |
| SCHEMBL6397687 | 0.77 | ACHE (0.54) | KDM4EL3MBTL3L3MBTL1KMT2ASLC18A3 | |
| SCHEMBL6057177 | 0.76 | ALDH1A1 (0.50) | KDM4EALDH1A1POLBKMT2AACE | |
| SCHEMBL6397839 | 0.75 | ACHE (0.39) | ALDH1A1SLC18A3ACE | |
| SCHEMBL6396689 | 0.74 | SIGMAR1 (0.37) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6404810 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | KDM4E 1902/4885ALDH1A1 1862/4885POLB 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.